Skip to main content
padlock icon - secure page this page is secure

Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy

Buy Article:

$59.00 + tax (Refund Policy)

Jordan K, Grothey A, Grothe W, Kegel T, Wolf H-H, Schmoll H-J. Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy.

Eur J Haematol 2005: 74: 263–266. © Blackwell Munksgaard 2005. Abstract: 

Lymphomatoid granulomatosis is a rare Epstein–Barr virus (EBV)-positive-B-cell lymphoproliferative disorder. Treatment options include corticosteroids, antiviral therapy, interferon-alpha and chemotherapy. However, long-term prognosis is poor and no therapeutic standard has been established yet. In a 21-year-old woman, a biopsy of mediastinal mass revealed lymphomatoid granulomatosis. Combined therapy with valganciclovir and interferon-alpha proved ineffective. In view of the CD20 expression of the tumor cells, monotherapy with rituximab was intiated. After 3 months a complete remission was achieved. Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CD20; EBV-associated lymphoproliferative disease; liebow granulomatosis; lymphomatoid granulomatosis; mediastinal bulk; rituximab

Document Type: Research Article

Publication date: March 1, 2005

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more